Evidence library 30 analyses
A research hub for NMN and NAD+ biology, covering human trials, dosing, safety, bioavailability and longevity claims.
Complete library
Browse every published guide, review and evidence update in this topic.
NMN has produced aerobic-capacity, walking and selected grip signals, but systematic evidence does not show reliable muscle growth. A 2026 BFR study adds an important exercise-adaptation caution.
NMN improved muscle insulin sensitivity in one major prediabetes trial, but meta-analyses show no consistent benefit for fasting glucose or HbA1c. Here's how both findings can be true.
A 2026 meta-analysis found a small average reduction in diastolic blood pressure, while overall systolic benefit was not significant. NMN is not established hypertension treatment.
Men are heavily represented in NMN trials, but testosterone, sperm, erectile-function and muscle-building claims remain unproven. This page separates male-specific data from marketing.
Women have direct NMN trial data for insulin sensitivity and preliminary hair research, while fertility benefits remain mouse-only and pregnancy safety is insufficient.
A 2025 single-arm study in 15 women reported hair-quality signals with 500 mg/day NMN, but no placebo-controlled evidence shows NMN treats hair loss or reverses gray hair.
NMN alters pigmentation biology in aged human melanocytes and reconstructed skin, but oral NMN has not been proven to reduce wrinkles or visibly reverse skin aging.
NMN changes NAD+ biology but has not produced reliable human weight loss. We compare the mouse metabolism story with randomized human trials, insulin-sensitivity data and the 2026 meta-analysis.
Formal NMN interaction studies are sparse. This guide separates proven evidence from theoretical overlap for diabetes drugs, blood-pressure medicines, chemotherapy, statins, anticoagulants and supplement stacks.
